Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Nexium and Cardi-04 yoghurt on insulin secretion, insulin action, and cardiovascular risk factors in patients with type 2 diabetes
2007-004052-37Phase 2Completed
- Sponsor
- Steno Diabetes Center
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of esomeprazole in type 2 diabetes mellitus (T2DM), cardiometabolic risk (CMR) and cardiac morbidity (4 arms), sponsored by Steno Diabetes Center. Primary endpoint: Insulin secretion AUC. Started Jan 2008; status: completed.
02
Drugs
esomeprazole
03
Conditions
type 2 diabetes mellitus (T2DM)cardiometabolic risk (CMR)cardiac morbidity
Beyond the preview
Go deeper on 2007-004052-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004052-37.